Compare AMTB & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | CSTL |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.2M | 661.7M |
| IPO Year | N/A | 2019 |
| Metric | AMTB | CSTL |
|---|---|---|
| Price | $20.49 | $39.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.75 | ★ $40.67 |
| AVG Volume (30 Days) | 251.0K | ★ 455.3K |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $388,504,000.00 | $343,530,000.00 |
| Revenue This Year | $61.42 | $1.69 |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 51.98 | 10.15 |
| 52 Week Low | $15.62 | $14.59 |
| 52 Week High | $25.03 | $40.61 |
| Indicator | AMTB | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 72.69 |
| Support Level | $20.31 | $37.76 |
| Resistance Level | $21.00 | $39.53 |
| Average True Range (ATR) | 0.49 | 1.31 |
| MACD | 0.12 | -0.40 |
| Stochastic Oscillator | 76.96 | 78.65 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.